Document is current
Any future updates will be listed below
-
Authors
Yoshiji, Satoshi https://orcid.org/0000-0001-8863-2413
Lu, Tianyuan https://orcid.org/0000-0002-5664-5698
Butler-Laporte, Guillaume https://orcid.org/0000-0001-5388-0396
Carrasco-Zanini-Sanchez, Julia https://orcid.org/0000-0002-3988-7505
Su, Chen-Yang https://orcid.org/0000-0001-6071-4660
Chen, Yiheng
Liang, Kevin
Willett, Julian Daniel Sunday https://orcid.org/0000-0002-8103-0329
Wang, Shidong
Adra, Darin
Ilboudo, Yann
Sasako, Takayoshi
Koyama, Satoshi https://orcid.org/0000-0002-9286-0360
Nakao, Tetsushi https://orcid.org/0000-0001-9979-2682
Forgetta, Vincenzo
Farjoun, Yossi
Zeberg, Hugo https://orcid.org/0000-0001-7118-1249
Zhou, Sirui https://orcid.org/0000-0003-4963-0815
Marks-Hultström, Michael https://orcid.org/0000-0003-4675-1099
Machiela, Mitchell J. https://orcid.org/0000-0001-6538-9705
Kaalia, Rama https://orcid.org/0000-0002-1305-0774
Dashti, Hesam
Claussnitzer, Melina https://orcid.org/0000-0003-2450-736X
Flannick, Jason https://orcid.org/0000-0002-3618-795X
Wareham, Nicholas J.
Mooser, Vincent https://orcid.org/0000-0002-8632-0448
Timpson, Nicholas J. https://orcid.org/0000-0002-7141-9189
Langenberg, Claudia https://orcid.org/0000-0002-5017-7344
Richards, J. Brent https://orcid.org/0000-0002-3746-9086
- License Information
-
More Information
Article History
Received: 27 April 2023
Accepted: 4 December 2024
First Online: 24 January 2025
Competing interests
: J.B.R. has served as an advisor to GlaxoSmithKline and Deerfield Capital. J.B.R.’s institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline, and Biogen for projects unrelated to this research. J.B.R. is the CEO of 5 Prime Sciences (), which provides research services for biotech, pharma and venture capital companies for projects unrelated to this research. T.L., Y.C. and V.F. are employees of 5 Prime Sciences. The remaining authors declare no competing interests.
